Exploring Key Insights of the Progressive Ataxia And Weakness Disorders Market: Growth Prospects, Emerging Trends, and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the progressive ataxia and weakness disorders market size evolved in recent years?
The market for progressive ataxia and weakness disorders has experienced swift expansion in the recent past. The market is estimated to escalate from $34.72 billion in 2024 to $38.67 billion in 2025, witnessing a compound annual growth rate (CAGR) of 11.4%. The phenomenal growth during the historic period is primarily due to factors such as heightened awareness and diagnosis, advancements in genetic research, enhanced government funding, rising health care expenditures, and an increase in alcohol and drug consumption.
What are the predictions for the progressive ataxia and weakness disorders market size in the coming years?
The progressive ataxia and weakness disorders market size is expected to see rapid growth in the next few years. It will grow to $58.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to the increasing prevalence of neurological disorders, the rising prevalence of chronic diseases, expanding insurance coverage, and the rising aging population. Major trends in the forecast period include technological advancements, genetic testing, gene therapy, personalized medicine, and the adoption of telemedicine.
Get your progressive ataxia and weakness disorders market report here!
What key factors are fueling the growth of the progressive ataxia and weakness disorders market?
The escalating occurrence of neurological diseases is projected to stimulate the expansion of the progressive ataxia and weakness disorders market. Neurological disorders, which affect the central and peripheral nervous systems including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles, are proliferating due to the aging population, genetic influences, and infectious ailments. Progressive ataxia and weakness disorders significantly contribute to neurology by directing diagnosis, treatment, research, and patient care strategies aimed at enhancing the results and life quality of those affected by these demanding neurological issues. For example, in April 2022, the European Brain Council, a non-profit organization based in Belgium, stated that the number of Europeans suffering from dementia (a neurological condition) stood at 10.5 million in 2022, with expectations to surge to 18.7 million by 2050. Accordingly, the escalating occurrence of neurological diseases propels the growth of the progressive ataxia and weakness disorders market.
How is the global progressive ataxia and weakness disorders market divided into key segments?
The progressive ataxia and weakness disorders market covered in this report is segmented –
1) By Type: Progressive Ataxia, Progressive Weakness Disorders
2) By Technology: Small Molecule, Monoclonal Antibody, Other Technology
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Progressive Ataxia: Cerebellar Ataxia, Sensory Ataxia, Vestibular Ataxia, Friedreich’s Ataxia, Spinocerebellar Ataxia (SCA), Idiopathic Ataxia
2) By Progressive Weakness Disorders: Amyotrophic Lateral Sclerosis (ALS), Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Myasthenia Gravis, Multiple Sclerosis (MS), Guillain-Barré Syndrome (GBS)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18444&type=smp
What are the top market players propelling the growth of the progressive ataxia and weakness disorders industry?
Major companies operating in the progressive ataxia and weakness disorders market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Banner Health, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Biohaven Pharmaceutical Holding Company Ltd., Design Therapeutics Inc., Anavex Life Sciences Corp., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Capsida Biotherapeutics Inc., Retrotope Inc., Taysha Gene Therapies Inc., CRISPR Therapeutics AG
How are evolving market trends shaping progressive ataxia and weakness disorders Strategies?
The market for progressive ataxia and weakness disorders is dominated by major corporations that are prioritizing the creation of ground-breaking products. This includes oral medications designed to treat Friedreich’s ataxia in adults and teenagers who are 16 years old and above. Oral medications, usually in the form of tablets, capsules, or liquid solutions, are ingested orally. For illustration, Biogen Inc., a biotechnology firm based in the US, reported in February 2024 that the European Commission (EC) had approved SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA). SKYCLARYS functions by triggering the Nrf2 pathway to tackle the oxidative stress and mitochondrial dysfunction that underlies Friedreich’s ataxia. This medication is consumed orally without food and has demonstrated a capacity to alleviate symptoms and decelerate disease advancement in clinical studies. Typical side effects encompass raised liver enzymes, headaches, nausea, abdominal discomfort, exhaustion, diarrhea, and pain in the musculoskeletal system.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18444
Which regions are most influential in expanding the progressive ataxia and weakness disorders market?
North America was the largest region in the progressive ataxia and weakness disorders market in 2023. The regions covered in the progressive ataxia and weakness disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Autism Spectrum Disorders Treatment Global Market Report 2024
Myeloproliferative Disorders Drugs Global Market Report 2024
Pigmentation Disorders Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
